Resultado de búsqueda
3 de jul. de 2021 · First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021 Jul 3;398 (10294):27-40. doi: 10.1016/S0140-6736 (21)00797-2. Epub 2021 Jun 5.
- Yelena Y Janjigian, Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salma...
- 2021
5 de jun. de 2021 · To our knowledge, CheckMate 649 is the first global study to show superior OS with a median OS exceeding 1 year in the first-line setting for patients with non-human epidermal growth factor receptor 2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma.
- Yelena Y Janjigian, Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salma...
- 2021
21 de feb. de 2024 · First-line nivolumab plus chemotherapy has been approved for the treatment of unresectable advanced, non–human epidermal growth factor receptor 2 (HER2)–positive gastric, gastroesophageal junction, and esophageal adenocarcinoma in over 50 countries on the basis of the results from CheckMate 649.
23 de mar. de 2022 · Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized,...
- Kohei Shitara
Abstract. 4002. Background: CheckMate 649 is the largest randomized, global phase 3 study of 1L programmed death (PD)-1 inhibitor–based therapy in GC/GEJC/EAC. 1L NIVO + chemo demonstrated superior overall survival (OS) vs chemo, with progression-free survival (PFS) benefit and an acceptable safety profile in pts whose tumors expressed PD ...
- Markus H. Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Y...
- 2021
19 de ene. de 2022 · Background: CheckMate 649 is a randomized, global phase 3 study of 1L programmed death-1 (PD-1) inhibitor–based therapies in advanced non-HER2-positive GC/GEJC/EAC that demonstrated superior overall survival (OS) with NIVO + chemo vs chemo, leading to approvals in the US and other countries.
We report 3-year efficacy and safety results from the phase III CheckMate 649 trial. Patients with previously untreated advanced or metastatic gastroesophageal adenocarcinoma were randomly assigned to nivolumab plus chemotherapy or chemotherapy.
